# CytoLynx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytolynx-therapeutics

- Industry: Biotechnology
- Headquarters: Miami, US
- Website: www.cytoviatx.com
- Total disclosed funding: $45M
- Latest round: Angel (Sep 13, 2021)
- Investors on record: 5

## About

Based in Miami, US and founded in 2021, CytoLynx Therapeutics is a developer of transformed cell therapy and immunotherapy. The company is a joint venture created by Cytovia and TF Capital. The company's co-founder, chairman and chief executive officer Dr. Teper, he was the founder and CEO of Immune Pharmaceuticals previously, he also served as New York-based managing partner at Bionest Partners. In September 2021, the company raised USD 45 million in angel funding.

The company focuses on Natural Killer (NK) cell biology and applies in induced pluripotent stem cells (iPSCs) to develop Natural Killer cell therapy as against cancer. The company’s multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site. 

The company aims to develop its medicine globally, with operations in the US, Europe, and China, and expand cell therapy beyond hematological malignancies to solid tumors.

## Funding rounds

- Angel, Sep 13, 2021, $45M — YF Capital, TF Capital, Everbright ReinFore, BioTrack Capital, Tigermed

## Investors

- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Angel
- TF Capital — Angel
- Everbright ReinFore (https://capitalatlas.ai/funds/everbright-reinfore) — Angel
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Angel
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Angel